KPS AG logo

KPS AG (KSC)

Market Open
12 Aug, 10:48
XSTU XSTU
0. 17
-0.01
-5.2632%
- Market Cap
- P/E Ratio
0.4% Div Yield
27,780 Volume
0 Eps
0.18
Previous Close
Add Transaction
Day Range
0.15 0.18
Year Range
0.15 0.76
Want to track KSC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

KSC trading today lower at €0.17, a decrease of -5.2632% from yesterday's close, completing a monthly decrease of -28.75% or -€0.07. Over the past 12 months, KSC stock lost -69.573%.
KSC is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
KPS AG has completed 3 stock splits, with the recent split occurring on Jun 30, 2016.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XSTU (EUR).

KSC Chart

KPS AG (KSC) FAQ

What is the stock price today?

The current price is €0.17.

On which exchange is it traded?

KPS AG is listed on XSTU.

What is its stock symbol?

The ticker symbol is KSC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.4%.

What is its market cap?

As of today, no market cap data is available.

Has KPS AG ever had a stock split?

KPS AG had 3 splits and the recent split was on Jun 30, 2016.

KPS AG Profile

Construction & Engineering Industry
Industrials Sector
Mr. Leonardo Musso CEO
XSTU Exchange
DE000A1A6V48 ISIN
Germany Country
547 Employees
11 May 2023 Last Dividend
30 Jun 2016 Last Split
- IPO Date

Overview

Lipidor AB (publ), headquartered in Danderyd, Sweden, is a pioneering pharmaceutical development company focusing on the creation of novel treatments for a variety of skin conditions. Since its inception in 2009, Lipidor has committed itself to addressing the therapeutic needs of patients suffering from psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. By advancing both preclinical and clinical-stage products, Lipidor aims to bring innovative solutions to the market. The company leverages a robust product pipeline, highlighted by its flagship AKP-01 treatment for psoriasis currently in Phase III development. With a strategic collaboration with Cannassure Therapeutics Ltd., Lipidor is expanding its horizon into the development of topical medicinal cannabis products, targeting skin inflammations and psoriatic lesions, underscoring its commitment to addressing unmet medical needs through cutting-edge research and development.

Products and Services

  • AKP-01 (Psoriasis Treatment)

    In active Phase III development, AKP-01 represents Lipidor's frontline treatment for psoriasis, showcasing the company's dedicated research in addressing chronic skin conditions with innovative therapeutic options.

  • Preclinical Stage Products

    - AKP-02 for Psoriasis: A promising candidate aimed at expanding Lipidor's psoriasis treatment portfolio.
    - AKP-03 for Bacterial Skin Diseases: Targeting a wide range of bacterial skin infections with a novel approach.
    - AKP-07 for Atopic Dermatitis: Focused on treating the challenging condition of atopic dermatitis, providing new hope for patients.

  • Active Pharmaceutical Ingredients (APIs)

    Lipidor offers a diverse range of APIs used in various therapeutic applications. These include anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine formulations, catering to a broad spectrum of healthcare needs.

  • Consumer Healthcare and Animal Skin Care

    Beyond pharmaceuticals for human healthcare, Lipidor extends its innovation to consumer health care products and animal skin care solutions. These offerings cover antibacterial, antiseptic, moisturizing emollient, disinfectant, acne and wart treatment for personal care, as well as specialized spray products for the skin care of dogs, cats, and horses, reflecting Lipidor's holistic approach to skin health.

  • Collaborative Development with Cannassure Therapeutics Ltd.

    Embarking on a collaboration with Cannassure Therapeutics Ltd., Lipidor is venturing into the development of topical medicinal cannabis products. This initiative specifically targets the treatment of skin inflammations and psoriatic lesions, illustrating Lipidor's strategic focus on leveraging partnerships to explore new therapeutic frontiers.

Contact Information

Address: Beta-Strasse 10 H
Phone: 49 89 35631 0
Website: https://kps.com